Sterinova, a new pharmaceutical company specialized in the development and manufacture of sterile ready-to-use injectable products, has inaugurated its plant in Saint-Hyacinthe and will offer syringes or premix solutions containers.

The new company, based in Saint-Hyacinthe, in the Montérégie region, is the result of a total investment of approximately $70 million, made by the Fonds de solidarité FTQ, Quebec Manufacturing Fund (QMF), Saint-Hyacinthe Technopole through the Pharmaceutical Development Centre for the construction of the building and the City of Saint-Hyacinthe for guarantee funding, Desjardins, Investissement Québec and Canada Economic Development for Quebec Regions (CED).

“Sterinova is one of the few pharmaceutical companies in the world to be entirely dedicated to the manufacture of ready-to-use injectable products. Its state-of-the-art technology and its production capacity will make Sterinova an important Canadian player on international markets,” said Jean-Philippe Gentès, president, Sterinova.

Located in the City of Biotechnology in Saint-Hyacinthe, one of the most important economic centers in Quebec and Eastern Canada, Sterinova is located at a site approved by Health Canada since 2015 for the manufacture of sterile biological products. The building of 6,225 square meters (67,000 square feet) was planned to allow to double its size. The plant is equipped with fully automated equipment and the whole production process meets the Canadian Good Manufacturing Practices (cGMP) and they have an objective to meets the European and U.S. requirements.